Serum choline is associated with hepatocellular carcinoma survival: a prospective cohort study

CURRENT STATUS: UNDER REVIEW

Nutrition & Metabolism  ・ BMC

Zhao-Yan Liu  
Sun Yat-Sen University  
ORCiD: 0000-0002-1345-0057

Dinuerguli Yishake  
Sun Yat-Sen University

Ai-Ping Fang  
Sun Yat-Sen University

Dao-Ming Zhang  
Sun Yat-Sen University

Gong-Cheng Liao  
Sun Yat-Sen University

Xu-Ying Tan  
Sun Yat-Sen University

Yao-Jun Zhang  
Sun Yat-sen University Cancer Center

Huilian Zhu  zhuhl@mail.sysu.edu.cn  
Corresponding Author  
ORCiD: 0000-0002-5019-2827

DOI: 10.21203/rs.2.19868/v1

SUBJECT AREAS  Endocrinology & Metabolism  Nutrition & Dietetics
KEYWORDS
choline, betaine, hepatocellular carcinoma, survival
Abstract

**Background:** Higher choline/betaine levels have been linked to lower risk of liver cancer, whereas existing data in relation to hepatocellular carcinoma (HCC) prognosis are scarce. Our objective was to examine the associations of the serum choline and betaine with HCC survival.

**Methods:** 866 newly diagnosed HCC patients were enrolled in the Guangdong Liver Cancer Cohort. Serum choline and betaine were assessed using high-performance liquid chromatography with online electro-spray ionization tandem mass spectrometry. Liver cancer-specific survival (LCSS) and overall survival (OS) were calculated. Cox proportional hazards models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs).

**Results:** Both LCSS (T3 vs. T1: HR=0.69, 95% CI: 0.51-0.94; \( P_{\text{trend}} < 0.05 \)) and OS (T3 vs. T1: HR=0.73, 95% CI: 0.54-0.99; \( P_{\text{trend}} < 0.05 \)) were better with sex-specific tertiles of serum choline levels. The associations were not significantly modified across strata of selected prognostic factors, except in the different C-reactive protein (CRP) levels, the favorable associations between serum choline and LCSS and OS were only existed among patients with CRP ≥3.0 mg/L. No significant associations were found between serum betaine levels and either LCSS or OS.

**Conclusions:** This study revealed that higher serum choline levels were associated with better HCC survival, especially in HCC patients with systemic inflammation status. No significant associations were found between serum betaine and HCC survival. Our finding might open new prospect in understanding the benefits of choline on HCC survival.

**Registration:** The Guangdong Liver Cancer Cohort was registered at
clinicaltrials.gov as NCT 03297255.

**Background**

Hepatocellular carcinoma (HCC) is one of the most common malignancy, and is a leading cause of cancer-related morbidity and mortality worldwide\(^1\). Multiple well-established ways aimed for curative treatment of HCC patients. However, the prognosis is still poor with five-year survival in the range of 5%-30\(^{\%}\)\(^2\). To improve long-term survival and diminish suffering of HCC patients, many convenient modifiable ways have been proposed to guide patient care, among which favorable dietary nutrients and nutritional status\(^3,4\) still remain as major challenges.

Choline is an essential nutrient present in all cells, and plays a wide range of physiological functions in the body\(^5\). For example, choline is important to maintain the structural integrity of cellular membranes by serving as a component of phosphatidylcholine, which comprises almost half of the cellular membranes\(^6\). And it is needed to form acetylcholine, an important signaling neurotransmitter\(^6\). In addition, choline occupies critical roles in maintaining normal liver function. Particularly, choline is a major source of methyl groups via oxidation to betaine, their functions involving the re-methylation of homocysteine to methionine are critical for DNA and histone methylation homeostasis, and therefore have been reported to be associated with cancer risk\(^2\) (including liver cancer) and survival\(^7-10\).

Experimental studies have reported that when deprived of choline, varying degrees of liver damages and liver diseases developed, including elevated transaminases\(^11\), affected lipid metabolism and transport\(^12\), fatty liver\(^13\), liver cirrhosis\(^13\) and even
liver cancer\textsuperscript{14}, whereas choline or betaine supplementation ameliorated liver
damage\textsuperscript{15, 16}, and choline supplementation increased global DNA methylation and
DNA methyltransferase expression in HepG2 cells\textsuperscript{17}, which implied that choline or
betaine might not only be associated with hepatocarcinogenesis, but also with liver
cancer survival. To date, although scarcely, three case control studies\textsuperscript{18-20} have
evaluated the relationship between choline/betaine and human liver cancer risk, in
which consistently favorable effects of choline were found. However, no existing
studies have reported the associations between choline/betaine and liver cancer
survival. Of note, men require more choline than women (recommended adequate
intake for choline: 425 mg/per day for women and 550 mg/per day for men\textsuperscript{21}), and
HCC happens much more common in men than women, yet previous studies
reported seriously insufficient dietary choline intake in Chinese population\textsuperscript{20, 22}, it
would be a very meaningful topic to investigate the influence of choline status on
HCC prognosis in Chinese population.
In this study, we aimed to examine serum choline and betaine in relation to HCC
survival in the Guangdong Liver Cancer Cohort (GLCC), to testify the hypothesis that
choline and betaine status would be associated with HCC survival.

Methods

Study population

GLCC is an ongoing prospective cohort study conducted at Sun Yat-sen University
Cancer Center (SYSUCC), the detailed protocols have been described previously\textsuperscript{23, 24}. The present analyses included adult HCC patients enrolled between September 2013 and February 2017 if they met all the following criteria: 1) diagnosed within 1
month, 2) had no history of other carcinoma or any anticancer therapy, 3) had donated available fasting blood samples. HCC was diagnosed by either imaging or histopathology based on National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers.

**Serum choline and betaine measurement**

Isolated fasting serum samples were assessed using high-performance liquid chromatography with online electro-spray ionization tandem mass spectrometry to measure the concentrations of choline, and betaine. Detailed protocol of choline measurement has been described previously. Detection of serum betaine was similar to choline, except for the internal standard was d9-betaine (obtained from Sigma-Aldrich, St. Louis, USA). The coefficients of variation for the between-run assays were 4.91% and 6.21% for choline and betaine, respectively.

**Survival data collection**

The date of recruitment was used as the start date of follow-up for GLCC patients, and the last outcome follow-up of the present study was conducted on September 26, 2017. We assessed liver cancer-specific survival (LCSS) and overall survival (OS), and deaths from liver cancer or all cause were assigned as outcome event of LCSS or OS, respectively. The ascertainment process of deaths has been described previously.

**Other covariates**

A structure questionnaire was used to collect sociodemographic and lifestyle data face-to-face by well-trained research staff. Current smokers or current alcohol drinkers were patients who smoked more than one cigarette per day or drank alcohol more than once per week continuously during past six months, and patients
who had abstinence of the habits were former smokers or former drinkers. Body mass index (BMI) was calculated based on height (m) and weight (kg) at diagnosis. In addition, education level, age at diagnosis, sex, residence and family history of primary liver cancer were also collected.

We retrospectively extracted examination, diagnostic and treatment data from the SYSUCC electronic medical records. Laboratory data at diagnosis included albumin (ALB), total bilirubin (TBIL), alkaline phosphatase (ALP), γ-glutaryl-transferase (GGT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), prothrombin time (PT), alpha fetoprotein (AFP), C-reactive protein (CRP), hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (Anti-HCV). A liver damage level was computed based on six liver function tests (ALB, TBIL, ALP, GGT, AST and ALT), cutoffs were described previously\textsuperscript{23}, the level was presented as 1 (no liver injury), 2 (possible minor injury), and $\geq 3$ (possible injury) in this study. Characteristics of HCC tumor and the non-tumoral liver were reviewed through imaging or pathology data at diagnosis, then Child-Pugh class\textsuperscript{26} and Barcelona Clinic Liver Cancer (BCLC) stage\textsuperscript{26} were determined. Treatments mainly included liver resection, intervention, radiofrequency ablation and others. In addition, presence of chronic diseases which can affect the prognosis of HCC were also collected, including hypertension, diabetes mellitus, fatty liver and cirrhosis.

**Statistical analysis**

The statistical analyses were computed in SPSS version 20.0 for WINDOWS (SPSS Inc, Chicago, IL, USA). All $P$-values were based on two-sided tests, $P < 0.05$ was considered statistically significant.

The serum levels of choline and betaine at diagnosis were mostly rescaled to sex-
specific tertiles (T) for analysis, except for the stratified analysis. Differences in basic characteristics across sex-specific tertiles of serum choline and betaine were compared by one-way analysis of variance (ANOVA), Kruskal-Wallis tests and Pearson’s Chi-Squared tests, where appropriate. Multivariate Cox proportional hazards models were used to examine the relationship between serum levels of choline and betaine and HCC survival outcomes. Hazard ratios (HRs) and 95% confidence interval (CI) were calculated with the first tertiles as the reference. Covariates were included into the models if the P-values of the nonparametric log-rank tests were <0.05. Finally, in model 1, nonclinical covariates such as age at diagnosis, sex, education level, residence, BMI and smoking status were selected to adjust. In model 2, significant clinical covariates were further adjusted, including AFP level (≥400 or <400 ng/L), CRP level (≥3.0 or <3 mg/L), baseline liver damage level, BCLC stage and treatments. Although the P-values of the nonparametric log-rank tests for the presence of fatty liver, presence of cirrhosis and Child-Pugh class were <0.05, they were not included in the multivariate analyses due to the multicollinearity with the baseline liver damage level or BCLC stage. Linear trends (P_trend) were evaluated by entering sex-specific tertiles of serum choline and betaine as continuous variables in the corresponding models. Stratified analyses were conducted to evaluate whether the relationships between serum choline/betaine and HCC survival would be modified by potential prognosis factors for HCC, including sex, age at diagnosis, BMI, smoking status, alcohol drinking status, serum folate level, AFP level, CRP level, baseline liver damage level, presence of fatty liver, presence of cirrhosis, BCLC stage and treatments. Interactions were estimated by including the multiplicative interaction terms in the multivariate models.
Results

**Patient characteristics**

Basic characteristics of the 866 HCC patients and comparisons of these characteristics by sex-specific tertiles of serum choline/betaine are presented in Table 1. The mean (±S.D.) age was 52.3±11.8 years. The median (IQR) levels of serum choline and betaine were 11.72 (9.52-14.92) μmol/L and 64.48 (52.44-77.65) μmol/L, respectively. Compared to subjects in the bottom sex-specific tertiles of serum choline, those in the top tertiles were older, were less likely to be current smokers, more likely to be former smokers and were less been diagnosed as BCLC C stage. Compared to patients in the bottom sex-specific tertiles of serum betaine, those in the top tertiles were more living in rural, more infected by HBV or HCV and less suffered from fatty liver.

**Associations between serum choline and betaine with HCC survival outcomes**

The median survival of HCC patients was 467 days (IQR: 227-835 days). During the follow-up, 291 (33.6%) deaths were documented, 270 (92.8%) of which were attributable to liver cancer. Both liver cancer-specific and overall mortality decreased with sex-specific tertiles of serum choline levels after adjusting for nonclinical factors in model 1, the associations became even stronger for further adjustment of traditional HCC prognostic factors in model 2, HRs (95% CIs) of liver cancer-specific and overall mortality (T3 vs T1) in model 2 were 0.69 (0.51-0.94) and 0.73 (0.54-0.99), respectively. Both $P_{\text{trend}}$ values were <0.05. However, no significant associations were found between serum betaine levels and either LCSS or OS in the fully-adjusted model 2 (all $P_{\text{trend}}$ values were >0.05). Data are
presented in Table 2.

**Stratified analyses**

Stratified analyses of serum choline/betaine levels by selected factors are shown in Table 3-4. No statistically significant multiplicative effect modifications were found across most of the aforementioned strata factors, either for LCSS or OS (all $P_{interaction} >0.05$). However, we observed significant multiplicative effect modifications by CRP level for serum choline. Compared to the first tertile of serum choline, patients in the third tertile had better survival in CRP $\geq$ 3.0 mg/L strata (HRs (95% CIs) of LCSS and OS (T3 vs T1) were 0.60 (0.41-0.88) and 0.63 (0.44-0.91), $P_{interaction}$ = 0.010 and 0.005, respectively.) but not in CRP <3.0 mg/L strata.

**Discussion**

To our best knowledge, this is the first study to examine serum choline and betaine in relation to HCC survival in a large cohort. We observed that higher serum choline levels at diagnosis were associated with better HCC survival, especially in those with systemic inflammation status (CRP level $\geq$ 3.0 mg/L), whereas serum betaine had no statistically significant associations with HCC survival outcomes.

Given its critically protective role for liver and other essential physiological functions in the body, it is not surprising that serum choline demonstrated favorable associations with HCC survival. First, choline is an essential nutrient for maintaining liver function. Liver is among the first organs to accumulate choline absorbed from the intestine and responsible for most of choline metabolism$^{27}$. Experimental studies have proved that choline deficiency might cause varying degrees of liver diseases ranging from dyslipidemia to liver cancer$^{27}$, whereas choline or betaine
supplementation could ameliorate liver damage\textsuperscript{15, 16}. Second, though choline is essential for maintaining normal liver function, its functions are more than this. It is indispensable for normal function of all cells, including the structural integrity of cell membranes and neurotransmission\textsuperscript{28}. Thus, sufficient choline can improve general health of HCC patients so as to further improve HCC survival outcomes. Third, choline is a major source of methyl group via oxidation to betaine, their important roles in methylation reactions are critical for DNA and histone methylation homeostasis. Jiang et al.\textsuperscript{17} used the human hepatic HepG2 cell to examine the effect of choline supplementation on DNA methylation, they found that choline supplementation increased both global DNA methylation and DNA methyltransferase expression, suggesting that choline could improve prognosis of HCC. However, in the present study, the favorable associations were only observed between serum choline and HCC survival outcomes, no statistically significant associations between serum betaine and HCC survival outcomes were found. These contradictory results implied that the protective effect of choline on HCC survival may not through the methylation metabolic pathway via oxidation to betaine. As a methyl donor, betaine participates in the re-methylation of homocysteine to methionine via the enzyme betaine homocysteine methyltransferase (BHMT)\textsuperscript{27}. However, this key enzyme is greatly reduced in HCC patients\textsuperscript{29}, and downregulation of BHMT in HCC associates with poor prognosis\textsuperscript{30}. Besides, after treating the Hepa 1–6 (derived cells from a mouse HCC model) and E47/C34 cell lines (clones of the HepG2 cell line) with exogenous S-adenosylmethionine (SAM) and betaine, results showed that SAM decreased the number of Hepa 1–6 and E47/C34 cells, and increased the number of dead cells in vitro, while betaine had no significant effect
either on the number of surviving cells or dead cells\textsuperscript{31}. Lastly, in the stratified analysis, we observed significant multiplicative effect modifications by CRP level, the favorable association between serum choline and HCC survival was only found in CRP $\geq$ 3.0 mg/L strata, but not in CRP < 3.0 mg/L strata. As a marker of systemic inflammation status, CRP has been identified as a useful prognostic factor for HCC\textsuperscript{32}. Our results implied that elevating serum choline may have more beneficial effects on HCC patients with systemic inflammation status.

Several strengths of this study should be noted. This is the first large prospective cohort study to investigate the associations of serum choline with HCC survival in a Chinese population, whose dietary choline intake were seriously insufficient\textsuperscript{20, 22}, thus the value of this study is significant and our findings may have impact for the design of future clinical trials. Quality control was strictly conducted in every step of this study, research staff were well-trained to collect the questionnaire information, all the data extracted from the SYSUCC electronic medical records were double checked, and serum choline/betaine concentrations were centrally measured in the same laboratory. Furthermore, to eliminate potential confounding factors as many as possible, we only included newly diagnosed HCC patients and collected sufficient information of the HCC patients, including both general and clinical prognostic factors.

However, some potential limitations should also be considered. We failed to collect the information of dietary habits changes and disease progression during the follow-up, and we had only one measurement of serum choline/betaine at diagnosis, due to the high mortality and poor prognosis of HCC, another time-consuming face-to-face interview and blood collection was extremely difficult, thus we cannot know the
circulating choline/betaine changes after diagnosis. In addition, it should be noted that our study is a preliminary epidemiological research, although to some extent, our finding had opened up new prospect in understanding the beneficial role of choline on HCC survival, we cannot explain the exact mechanisms restricted by the observational study design, further investigations such as randomized clinical trials are warranted to confirm these findings.

Conclusions
In conclusion, the key findings from this large prospective cohort study revealed that higher serum choline levels at diagnosis were associated with better HCC survival outcomes, independently from representative nonclinical and clinical prognostic factors, especially in HCC patients with systemic inflammation status. Further investigations such as randomized clinical trials are warranted to confirm these findings.

Abbreviations
HCC, hepatocellular carcinoma; GLCC, Guangdong Liver Cancer Cohort; LCSS, Liver cancer-specific survival; OS, overall survival; HRs, hazard ratios; CIs, confidence intervals; SYSUCC, Sun Yat-sen University Cancer Center; PLC, primary liver cancer; T1, first tertile; T2, second tertile; T3, third tertile; BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, alpha fetoprotein; CRP, C-reactive protein; BCLC, Barcelona Clinic Liver Cancer; ALB, albumin; TBIL, total bilirubin; ALP, alkaline phosphatase; GGT, γ-glutaryl-transferase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PT, prothrombin time; SAM, S-adenosylmethionine; BHMT, betaine homocysteine methyltransferase.
Declarations

**Ethics approval and consent to participate**

The Ethics Committee of the School of Public Health at Sun Yat-sen University approved the protocol of this study. Written informed consent was obtained from all participants. The study was performed in accordance with the Declaration of Helsinki.

**Consent for publication**

Not applicable.

**Availability of data and materials**

The datasets generated and/or analyzed during the current study are not publicly available due to privacy protection of the participants but are available from the corresponding author on reasonable request.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This research was funded by the National Natural Science Foundation of China, grant number 81973016 and 81803219, and the Natural Science Foundation of Guangdong Province, China, grant number 2018A030310335.

**Authors' contributions**

ZYL performed the study design, data analysis and drafted the manuscript. HLZ, YJZ and APF administrated the project. DY, DMZ, GCL and XYT collected the data and blood samples, and conducted the choline and betaine analysis. All authors read and approved the final manuscript.

**Acknowledgements**
We thank all the HCC patients and research stuff for their contributions to this study.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2018;68:394-424.

2. Youn J, Cho E, Lee JE. Association of choline and betaine levels with cancer incidence and survival: A meta-analysis. Clinical nutrition (Edinburgh, Scotland) 2019;38(1):100-09.

3. Diet, nutrition, physical activity and liver cancer. World cancer research fund/American Institute for Cancer Research; Available at dietandcancerreport.org.

4. Harding JJ, Khalil DN, Abou-Alfa GK. Biomarkers: What Role Do They Play (If Any) for Diagnosis, Prognosis and Tumor Response Prediction for Hepatocellular Carcinoma? Digestive diseases and sciences 2019;64(4):918-27.

5. Hollenbeck CB. An Introduction to the Nutrition and Metabolism of Choline. Central Nervous System Agents in Medicinal Chemistry 2012;12:100-13.

6. Zeisel SH. Choline: Critical Role During Fetal Development and Dietary Requirements in Adults. Annu Rev Nutr. 2006;26:229-50.

7. Richman EL, Kenfield SA, Stampfer MJ, Giovannucci EL, Zeisel SH, Willett WC, Chan JM. Choline intake and risk of lethal prostate cancer: incidence and survival. The American journal of clinical nutrition 2012;96:855-63.

8. Dixon SC, Ibiebele TI, Protani MM, Beesley J, deFazio A, Crandon AJ, Gard GB,
Rome RM, Webb PM, Nagle CM, Australian Ovarian Cancer Study G. Dietary folate and related micronutrients, folate-metabolising genes, and ovarian cancer survival. Gynecol Oncol 2014;132:566-72.

9. Galvan-Portillo MV, Onate-Ocana LF, Perez-Perez GI, Chen J, Herrera-Goepfert R, Chihu-Amparan L, Flores-Luna L, Mohar-Betancourt A, Lopez-Carrillo L. Dietary folate and vitamin B12 intake before diagnosis decreases gastric cancer mortality risk among susceptible MTHFR 677TT carriers. Nutrition (Burbank, Los Angeles County, Calif.) 2010;26:201-8.

10. Xu X, Gammon MD, Zeisel SH, Bradshaw PT, Wetmur JG, Teitelbaum SL, Neugut AI, Santella RM, Chen J. High intakes of choline and betaine reduce breast cancer mortality in a population-based study. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2009;23:4022-28.

11. Alan L. Buchman MEA, Mir Sohel, Mark Dubin, Donald J. Jenden, Margaret Roch, et al. Choline Deficiency Causes Reversible Hepatic Abnormalities in Patients Receiving Parenteral Nutrition: Proof of a Human Choline Requirement: A Placebo-Controlled Trial. Journal of Parenteral and enteral nutrition 2001;25:260-8.

12. McNeil CJ, Hay Sm Fau - Rucklidge Gj, Rucklidge Gj Fau - Reid M, Reid M Fau - Duncan G, Duncan G Fau - Maloney CA, Maloney Ca Fau - Rees WD, Rees WD. Disruption of lipid metabolism in the liver of the pregnant rat fed folate-deficient and methyl donor-deficient diets. The British journal of nutrition 2008;99(2):262-71.

13. Sherriff JL, O'Sullivan TA, Properzi C, Oddo JL, Adams LA. Choline, Its Potential Role in Nonalcoholic Fatty Liver Disease, and the Case for Human and Bacterial
14. Mato JM, Lu SC. The hepatocarcinogenic effect of methionine and choline deficient diets: an adaptation to the Warburg effect? Alcoholism, clinical and experimental research 2011;35(5):811-4.

15. Erina KITAGAWA YO, Maki HASEGAWA, Tomoyuki NAKAGAWA and Takashi HAYAKAWA. Accumulation of Liver Lipids Induced by Vitamin B6 Deficiency Was Effectively Ameliorated by Choline and, to a Lesser Extent, Betaine. J Nuti Sci Vitaminol 2019;65:94-101.

16. Kitagawa E, Yamamoto T, Fujishita M, Ota Y, Yamamoto K, Nakagawa T, Hayakawa T. Choline and betaine ameliorate liver lipid accumulation induced by vitamin B6 deficiency in rats. Bioscience, biotechnology, and biochemistry 2017;81:316-22.

17. Jiang X, Greenwald E, Jack-Roberts C. Effects of Choline on DNA Methylation and Macronutrient Metabolic Gene Expression in In Vitro Models of Hyperglycemia. Nutrition and metabolic insights 2016;9:11-7.

18. Butler LM, Arning E, Wang R, Bottiglieri T, Govindarajan S, Gao YT, Yuan JM. Prediagnostic levels of serum one-carbon metabolites and risk of hepatocellular carcinoma. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2013;22:1884-93.

19. Liu Z-Y, Tan X-Y, Li Q-J, Liao G-C, Fang A-P, Zhang D-M, Chen P-Y, Wang X-Y, Luo Y, Long J-A, Zhong R-H, Zhu H-L. Trimethylamine N-oxide, a gut microbiota-dependent metabolite of choline, is positively associated with the risk of primary liver cancer: a case-control study. Nutrition & Metabolism 2018;15:81.

20. Zhu HL, Huang J, Xu M, Fang YJ, Lu MS, Pan ZZ, Huang WQ, Chen YM, Zhang CX.
Higher dietary intakes of choline and betaine are associated with a lower risk of primary liver cancer: a case-control study. Scientific reports 2017;117:839-50.

21. Yates AA, Schlicker SA, Suitor CW. Dietary Reference Intakes. Journal of the American Dietetic Association 1998;98:699-706.

22. Zeng FF, Xu CH, Liu YT, Fan YY, Lin XL, Lu YK, Zhang CX, Chen YM. Choline and betaine intakes are associated with reduced risk of nasopharyngeal carcinoma in adults: a case-control study. British journal of cancer 2014;110:808-16.

23. Fang AP, Chen PY, Wang XY, Liu ZY, Zhang DM, Luo Y, Liao GC, Long JA, Zhong RH, Zhou ZG, Xu YJ, Xu XJ, et al. Serum Copper and Zinc levels at Diagnosis and Hepatocellular Carcinoma Survival in the Guangdong Liver Cancer Cohort. International journal of cancer 2019;144(11):2823-32.

24. Fang AP, Liu ZY, Liao GC, Chen PY, Wang XY, Zhang DM, Luo Y, Long JA, Zhong RH, Zhou ZG, Xu YJ, Xu XJ, et al. Serum folate concentrations at diagnosis are associated with hepatocellular carcinoma survival in the Guangdong Liver Cancer Cohort study. The British journal of nutrition 2019:1-38.

25. Al B. Benson III TAA, Edgar Ben-Josef, P. Mark Bloomston, Jean F. Botha, Bryan M. Clary, et al. Hepatobiliary Cancers: Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN 2009;7:350-91.

26. Cillo U, Vitale A, Grigoletto F, Farinati F, Broplese A, Zanus G, Neri D, Boccagni P, Srsen N, D'Amico F, Ciarleglio FA, Bridda A, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. Journal of hepatology 2006;44:723-31.

27. Mehedint MG, Zeisel SH. Choline's role in maintaining liver function: new evidence for epigenetic mechanisms. Current opinion in clinical nutrition and
metabolic care 2013;16:339-45.

28. Wiedeman AM, Barr SI, Green TJ, Xu Z, Innis SM, Kitts DD. Dietary Choline Intake: Current State of Knowledge Across the Life Cycle. Nutrients 2018;10:1513.

29. Pellanda H. Betaine homocysteine methyltransferase (BHMT)-dependent remethylation pathway in human healthy and tumoral liver. Clinical chemistry and laboratory medicine 2013;51:617-21.

30. Jin B, Gong Z, Yang N, Huang Z, Zeng S, Chen H, Hu S, Pan G. Downregulation of betaine homocysteine methyltransferase (BHMT) in hepatocellular carcinoma associates with poor prognosis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2016;37:5911-7.

31. Oliva J, Zhong J, Buslon VS, French SW. The effect of SAMe and betaine on Hepa 1-6, C34 and E47 liver cell survival in vitro. Experimental and molecular pathology 2012;92:126-30.

32. Sieghart W, Pinter M, Hucke F, Graziadei I, Schoniger-Hekele M, Muller C, Vogel W, Trauner M, Peck-Radosavljevic M. Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. Hepatology (Baltimore, Md.) 2013;57:2224-34.

Tables

Table 1. Patient characteristics at diagnosis by sex-specific tertiles of serum choline/betaine levels

| All patients | Serum choline | Serum betaine |
|--------------|---------------|---------------|
|              | T1            | T3            | P-value | T1            | T3            | P-value |
| Age at diagnosis | 52.3±11.8 | 50.2±11.9 | 53.8±11.7 | 0.00 | 51.6±11.7 | 51.6±11.7 | 0.37 |
| a, years | 770 | 257 | 256 | 0.98 | 256 | 256 | 1.00 |
| Men, n   |   |   |   |   |   |   |   |
| (%) | (88.9)  | (88.6)  | (89.2)  | 0.34 | (88.9)  | (88.9)  | 0.68 |
|-----|---------|---------|---------|------|---------|---------|------|
| BMI at diagnosis | 22.7±3.3 | 22.5±3.3 | 22.7±3.3 | 0.34 | 22.5±3.0 | 22.5±3.0 | 0.68 |
| a, kg/m² | 0.37 | 0.45 |
| Education level, n (%) | 171 (19.8) | 56 (19.4) | 52 (18.1) | 62 (21.7) | 61 (21.2) |
| Primary school or below | 528 (61.2) | 168 (58.3) | 183 (63.8) | 175 (61.2) | 169 (58.7) |
| Secondar y & High school | 164 (19.0) | 64 (22.2) | 52 (18.1) | 49 (17.1) | 58 (20.1) |
| College or above | 0.60 | 0.03 |
| Residence , n (%) | 595 (68.7) | 195 (67.2) | 195 (67.9) | 215 (74.7) | 188 (65.3) |
| Urban | 271 (31.3) | 95 (32.8) | 92 (32.1) | 73 (25.3) | 100 (34.7) |
| Rural | 0.00 | 0.06 |
| Smoking status, n (%) | 265 (30.6) | 101 (34.8) | 74 (25.8) | 106 (36.8) | 78 (27.1) |
| Current | 241 (27.8) | 55 (19.0) | 100 (34.8) | 71 (24.7) | 90 (31.2) |
| former | 360 (41.6) | 134 (46.2) | 113 (39.4) | 111 (38.5) | 120 (41.7) |
| Never | 0.57 | 0.73 |
| Alcohol drinking status, n (%) | 789 (91.1) | 269 (92.8) | 257 (89.5) | 0.40 | 254 (88.2) | 274 (95.1) | 0.01 |
| Current | 112 (12.9) | 46 (15.9) | 33 (11.5) | 0.19 | 37 (12.8) | 36 (12.5) | 0.94 |
| former | 0.00 | 0.06 |
| Never | 505 (58.3) | 168 (57.9) | 160 (55.7) | 172 (59.7) | 166 (57.6) |
| With family history of PLC, n (%) | 111 (12.8) | 28 (9.7) | 39 (13.6) | 0.12 | 34 (11.7) | 111 (12.8) | 0.31 |
| HBV or HCV infected, n (%) | 358 (41.4) | 112 (38.9) | 116 (40.4) | 0.30 | 124 (43.2) | 110 (38.2) | 0.39 |
| AFP≥400 ng/L, n (%) | 436 (50.6) | 148 (51.6) | 149 (52.1) | 0.61 | 138 (48.1) | 161 (56.3) | 0.06 |
| CRP≥3.0 mg/L, n (%) | 0.00 | 0.06 |
| Presence of chronic diseases, n (%) | 111 (12.8) | 28 (9.7) | 39 (13.6) | 0.12 | 34 (11.7) | 111 (12.8) | 0.31 |
| Hypertension | 69 (8.0) | 19 (6.6) | 29 (10.1) | 0.25 | 30 (10.4) | 17 (5.9) | 0.13 |
| Diabetes mellitus | 143 (16.5) | 44 (15.2) | 49 (17.1) | 0.75 | 64 (22.2) | 32 (11.1) | 0.00 |
| Fatty liver | 544 (62.8) | 176 (60.7) | 182 (63.4) | 0.64 | 175 (60.8) | 193 (67.0) | 0.20 |
| Cirrhosis | 0.87 | 0.16 |
| Baseline liver damage level, n (%) | 172 (19.9) | 58 (20.0) | 52 (18.1) | 60 (20.8) | 54 (18.8) |
| 1 | 334 (38.6) | 109 (37.6) | 116 (40.4) | 95 (33.0) | 116 (40.3) |
| 2 | 360 (41.6) | 123 (42.4) | 119 (41.5) | 133 (46.2) | 118 (40.3) |
| ≥3 | 0.00 | 0.06 |
### Table 2. Survival outcomes by sex-specific tertiles of serum choline and betaine levels

| Child-Pugh class, n (%) | 0.45 (97.6) | 282 (98.3) | 286 (99.3) | 280 (97.2) |
|------------------------|-------------|------------|------------|------------|
| A                      | 851 (98.3)  | 7 (2.4)    | 2 (0.7)    | 8 (2.8)    |
| B                      | 15 (1.7)    | 101 (44.3) | 121 (42.1) | 127 (44.1) |
| C                      | 423 (48.8)  | 162 (55.9) | 267 (35.5) | 127 (44.1) |
| Treatments, n (%)      | 0.61        | 0.18       | 0.03       | 0.03       |
| Liver resection        | 383 (44.2)  | 132 (45.5) | 127 (44.3) | 133 (46.2) |
| Radiofrequency ablation| 85 (9.8)    | 31 (10.7)  | 26 (9.1)   | 21 (7.3)   |
| Intervention Others    | 41 (4.7)    | 18 (6.2)   | 13 (4.5)   | 10 (3.5)   |
| Serum choline<sup>b</sup> (μmol/L) | 11.72 (8.13-14.94) | 18.14 (20.36-23.18) | 10.48 (8.93-12.97) | 12.97 (10.37-17.11) |
| Serum betaine<sup>b</sup> (μmol/L) | 64.48 (59.08-70.24) | 73.65 (85.95-90.38) | 48.19 (42.13-53.35) | 83.72 (77.65-94.46) |
| Serum folate<sup>b</sup> (μmol/L) | 7.04 (5.30-8.90) | 8.29 (9.87-10.37) | 6.75 (5.05-8.87) | 7.00 (5.20-9.44) |

<sup>a</sup> values are expressed as mean ± S.D.; <sup>b</sup> values are expressed as median (IQR).
Liver cancer-specific survival

Serum choline

|          | T1       | T2       | T3       | \( P \) <sup>-trend</sup> | \( P \) <sup>-interaction</sup> |
|----------|----------|----------|----------|-----------------------------|---------------------------------|
| Deaths / Total cases | 87 / 290 | 84 / 289 | 99 / 287 |                            |                                 |
| Person-days at risk  | 122905   | 143328   | 202856   |                            |                                 |
| Model 1-adjusted HR (95% CI) <sup>a</sup> | 1.00     | 0.83 (0.61-1.13) | 0.73 (0.55-0.99) |                        |                                 |
| Model 2-adjusted HR (95% CI) <sup>b</sup> | 1.00     | 0.84 (0.62-1.15) | 0.69 (0.51-0.94) |                        |                                 |

Serum betaine

|          | T1       | T2       | T3       | \( P \) <sup>-trend</sup> | \( P \) <sup>-interaction</sup> |
|----------|----------|----------|----------|-----------------------------|---------------------------------|
| Deaths / Total cases | 90 / 288 | 94 / 290 | 86 / 288 |                            |                                 |
| Person-days at risk  | 149722   | 156715   | 162652   |                            |                                 |
| Model 1-adjusted HR (95% CI) <sup>a</sup> | 1.00     | 0.94 (0.70-1.26) | 0.85 (0.63-1.15) |                        |                                 |
| Model 2-adjusted HR (95% CI) <sup>b</sup> | 1.00     | 0.97 (0.72-1.31) | 0.84 (0.62-1.13) |                        |                                 |

Overall survival

Serum choline

|          | T1       | T2       | T3       | \( P \) <sup>-trend</sup> | \( P \) <sup>-interaction</sup> |
|----------|----------|----------|----------|-----------------------------|---------------------------------|
| Deaths / Total cases | 90 / 290 | 91 / 289 | 110 / 287 |                            |                                 |
| Person-days at risk  | 122905   | 143328   | 202856   |                            |                                 |
| Model 1-adjusted HR (95% CI) <sup>a</sup> | 1.00     | 0.85 (0.63-1.14) | 0.78 (0.58-1.05) |                        |                                 |
| Model 2-adjusted HR (95% CI) <sup>b</sup> | 1.00     | 0.85 (0.62-1.15) | 0.73 (0.54-0.99) |                        |                                 |

Serum betaine

|          | T1       | T2       | T3       | \( P \) <sup>-trend</sup> | \( P \) <sup>-interaction</sup> |
|----------|----------|----------|----------|-----------------------------|---------------------------------|
| Deaths / Total cases | 97 / 288 | 99 / 290 | 95 / 288 |                            |                                 |
| Person-days at risk  | 149722   | 156715   | 162652   |                            |                                 |
| Model 1-adjusted HR (95% CI) <sup>a</sup> | 1.00     | 0.93 (0.70-1.24) | 0.88 (0.66-1.17) |                        |                                 |
| Model 2-adjusted HR (95% CI) <sup>b</sup> | 1.00     | 0.95 (0.72-1.27) | 0.84 (0.63-1.13) |                        |                                 |

\( a \) Covariates adjusted in Model 1: age, sex, BMI, education level, smoking status.

\( b \) Covariates adjusted in Model 2: covariates adjusted in Model 1, additionally adjusted for baseline liver damage level, BCLC stage, treatment, AFP level and CRP level.

Table 3. HR (95% CI) of stratified analysis across tertiles of serum choline levels

|          | T1       | T2       | T3       | \( P \) <sup>-trend</sup> | \( P \) <sup>-interaction</sup> |
|----------|----------|----------|----------|-----------------------------|---------------------------------|
| Sex <sup>a</sup> <sup>b</sup> |                       |          |          |                              |                                 |
| Men      | 1.00     | 0.77     | 0.66     | 0.013                       | 0.08                          |
| Wome     | 1.00     | 1.21     | 1.59     | 0.360                       | 0.10                          |

\( a \) Covariates adjusted in Model 1: age, sex, BMI, education level, smoking status.

\( b \) Covariates adjusted in Model 2: covariates adjusted in Model 1, additionally adjusted for baseline liver damage level, BCLC stage, treatment, AFP level and CRP level.
|                      | n      | (0.41-3.52) | (0.57-4.44) | (0.42-3.14) | (0.50-3.54) | 0.838 | 0.801 |
|----------------------|--------|-------------|-------------|-------------|-------------|-------|-------|
| Age a, b, years      | <60    | 1.00        | 1.03        | 0.69        | 0.031       | 1.00  | 1.07  | 0.74  | 0.070 |
|                      |        | (0.72-1.48) | (0.48-0.99) | (0.75-1.52) | (0.52-1.06) |       |       |
|                      | ≥60    | 1.00        | 0.80        | 0.63        | 0.142       | 1.00  | 0.83  | 0.65  | 0.155 |
|                      |        | (0.42-1.51) | (0.34-1.17) | (0.45-1.53) | (0.36-1.18) |       |       |
| BMI a, b, kg/m^2     | <25.0  | 1.00        | 0.90        | 0.74        | 0.079       | 1.00  | 0.88  | 0.77  | 0.117 |
|                      |        | (0.64-1.27) | (0.53-1.04) | (0.62-1.23) | (0.55-1.07) |       |       |
|                      | ≥25.0  | 1.00        | 1.15        | 0.47        | 0.118       | 1.00  | 1.03  | 0.61  | 0.185 |
|                      |        | (0.54-2.44) | (0.20-1.10) | (0.50-2.12) | (0.28-1.32) |       |       |
| Smoking status a, b  | Smoker | 1.00        | 0.58        | 0.57        | 0.010       | 1.00  | 0.61  | 0.61  | 0.013 |
|                      |        | (0.39-0.85) | (0.39-0.83) | (0.42-0.89) | (0.42-0.88) |       |       |
|                      | Non-somker | 1.00        | 1.17        | 0.85        | 0.481       | 1.00  | 1.19  | 0.91  | 0.669 |
|                      |        | (0.69-1.98) | (0.50-1.42) | (0.71-2.01) | (0.55-1.51) |       |       |
| Drinking status a, b | Drinker | 1.00        | 0.67        | 0.78        | 0.342       | 1.00  | 0.71  | 0.75  | 0.237 |
|                      |        | (0.41-1.07) | (0.50-1.22) | (0.44-1.13) | (0.48-1.16) |       |       |
|                      | Non-drinker | 1.00        | 1.23        | 0.72        | 0.077       | 1.00  | 1.16  | 0.74  | 0.135 |
|                      |        | (0.82-1.86) | (0.47-1.12) | (0.77-1.74) | (0.49-1.13) |       |       |
| AFP level a, b ng/mL | ≥400   | 1.00        | 0.85        | 0.80        | 0.300       | 1.00  | 0.86  | 0.83  | 0.385 |
|                      |        | (0.56-1.30) | (0.52-1.22) | (0.57-1.29) | (0.56-1.25) |       |       |
|                      | <400   | 1.00        | 0.87        | 0.68        | 0.085       | 1.00  | 0.91  | 0.73  | 0.155 |
|                      |        | (0.55-1.37) | (0.43-1.06) | (0.58-1.42) | (0.48-1.13) |       |       |
| CRP level a, b mg/L  | ≥3.0   | 1.00        | 0.91        | 0.60        | 0.008       | 1.00  | 0.92  | 0.63  | 0.013 |
|                      |        | (0.64-1.29) | (0.41-0.88) | (0.65-1.29) | (0.44-0.91) |       |       |
|                      | <3.0   | 1.00        | 1.34        | 1.37        | 0.353       | 1.00  | 1.34  | 1.47  | 0.224 |
|                      |        | (0.70-2.56) | (0.74-2.51) | (0.71-2.54) | (0.81-2.67) |       |       |
| Serum folate level a, b | High | 1.00        | 1.07        | 0.79        | 0.279       | 1.00  | 1.17  | 0.91  | 0.583 |
|                      |        | (0.67-1.70) | (0.50-1.26) | (0.74-1.84) | (0.58-1.43) |       |       |
|                      | Low    | 1.00        | 0.96        | 0.77        | 0.207       | 1.00  | 0.94  | 0.76  | 0.170 |
|                      |        | (0.62-1.47) | (0.50-1.17) | (0.62-1.42) | (0.50-1.14) |       |       |
| Liver damage         |        |             |             |             |             | 0.520 | 0.602 |     |      |
| Level | 1  | 2  | 3  | \(
|-------|----|----|----|\) |
|       | 1.00 | 1.00 | 1.00 | 1.00 |
|       | (0.34-5.74) | (0.63-1.78) | (0.55-1.22) | (0.55-1.22) |
|       | 1.54 | 0.58 | 0.72 | 1.08 |
|       | (0.40-6.00) | (0.33-1.01) | (0.48-1.22) | (0.48-1.22) |
|       | 0.547 | 0.045 | 0.115 | 0.115 |
|       | (0.34-5.74) | (0.38-1.39) | (0.48-1.22) | (0.48-1.22) |
|       | 1.00 | 1.00 | 1.00 | 1.00 |
|       | (0.34-5.74) | (0.38-1.39) | (0.48-1.22) | (0.48-1.22) |
|       | 0.935 | 0.58 | 0.045 | 0.58 |
|       | (0.52-6.62) | (0.53-6.00) | (0.58-6.00) | (0.58-6.00) |

Presence of fatty liver a, b

|       | 0.385 | 0.842 |
|       | (0.52-6.62) | (0.53-6.00) |

Presence of cirrhosis a, b

|       | 0.518 | 0.170 |
|       | (0.52-6.00) | (0.53-6.00) |

BCLC stage a, b

|       | 0.774 | 0.502 |
|       | (0.52-6.00) | (0.53-6.00) |

Treatment a, b

|       | 0.333 | 0.480 |
|       | (0.48-1.21) | (0.48-1.21) |

Liver resection

|       | 1.00 | 1.00 | 1.00 | 1.00 |
|       | (0.69-2.41) | (0.51-1.10) | (0.52-3.07) | (0.52-3.07) |
|       | 1.29 | 0.75 | 1.26 | 0.95 |
|       | (0.42-2.41) | (0.41-1.10) | (0.37-2.42) | (0.37-2.42) |
|       | 0.81 | 0.60 | 0.95 | 0.90 |
|       | (0.42-2.41) | (0.41-1.10) | (0.37-2.42) | (0.37-2.42) |
|       | 0.536 | 0.006 | 0.908 | 0.908 |
|       | (0.42-2.41) | (0.41-1.10) | (0.37-2.42) | (0.37-2.42) |
|       | 1.16 | 1.00 | 1.21 | 1.00 |
|       | (0.46-2.14) | (0.40-2.94) | (0.40-2.94) | (0.40-2.94) |
|       | 0.87 | 0.64 | 1.00 | 1.00 |
|       | (0.46-2.14) | (0.40-2.94) | (0.40-2.94) | (0.40-2.94) |
|       | 0.664 | 0.015 | 0.985 | 0.985 |
|       | (0.46-2.14) | (0.40-2.94) | (0.40-2.94) | (0.40-2.94) |

Table 4. HR (95% CI) of stratified analysis across tertiles of serum betaine levels

| Liver cancer-specific survival | T1  | T2  | T3  | \(P\)-trend | \(P\)-interaction |
|-------------------------------|-----|-----|-----|-------------|------------------|
| Sex a, b                      |     |     |     |             | 0.229            |
| Men                           | 1.00| 0.95| 0.73|             | 0.046            |

**a** Covariates adjusted for age, sex, BMI, education level, smoking status, baseline liver damage level, BCLC stage, treatment, AFP level and CRP level.

**b** Stratified factors were not included in the corresponding models.
| Women | 1.00 | 1.29 | 0.99 | 1.30 | 0.99 | 0.91 | 0.30-2.74 | 0.45-3.74 | 0.590 |
|-------|------|------|------|------|------|------|-----------|-----------|-------|
| Age a, b, years | 1.00 | 1.01 | 0.91 | 1.01 | 0.91 | 0.91 | 0.72-1.43 | 0.62-1.25 | 0.460 |
| <60 | 1.00 | 1.17 | 0.86 | 1.17 | 0.86 | 0.86 | 0.65-2.13 | 0.47-1.58 | 0.586 |
| ≥60 | 1.00 | 1.01 | 0.85 | 1.01 | 0.85 | 0.85 | 0.73-1.39 | 0.61-1.18 | 0.331 |
| BMI a, b, kg/m² | 1.00 | 1.17 | 1.78 | 1.17 | 1.78 | 1.78 | 0.89-4.75 | 0.76-4.15 | 0.218 |
| <25.0 | 1.00 | 1.25 | 0.87 | 1.25 | 0.87 | 0.87 | 0.81-1.51 | 0.55-1.37 | 0.609 |
| ≥25.0 | 1.00 | 1.03 | 0.87 | 1.03 | 0.87 | 0.87 | 0.69-1.45 | 0.55-1.37 | 0.609 |
| Smoking status a, b | 1.00 | 1.16 | 0.96 | 1.16 | 0.96 | 0.96 | 0.81-1.68 | 0.62-1.11 | 0.153 |
| Smoker | 1.00 | 0.90 | 0.78 | 1.04 | 0.90 | 0.90 | 0.54-1.50 | 0.64-1.69 | 0.884 |
| Non-smoker | 1.00 | 0.99 | 0.98 | 0.99 | 0.98 | 0.98 | 0.67-1.46 | 0.52-1.17 | 0.226 |
| Drinking status a, b | 1.00 | 1.03 | 0.87 | 1.03 | 0.87 | 0.87 | 0.59-1.12 | 0.38-1.31 | 0.446 |
| Drinker | 1.00 | 1.27 | 0.86 | 1.27 | 0.86 | 0.86 | 0.82-1.96 | 0.54-1.37 | 0.545 |
| Non-Drinker | 1.00 | 1.03 | 0.92 | 1.03 | 0.92 | 0.92 | 0.68-1.54 | 0.62-1.38 | 0.695 |
| AFP level a, b, ng/mL | 1.00 | 1.03 | 0.63 | 1.03 | 0.63 | 0.63 | 0.69-1.54 | 0.45-1.45 | 0.853 |
| ≥400 | 1.00 | 1.25 | 0.87 | 1.25 | 0.87 | 0.87 | 0.81-1.95 | 0.55-1.37 | 0.609 |
| <400 | 1.00 | 0.96 | 0.98 | 0.96 | 0.98 | 0.98 | 0.61-1.51 | 0.62-1.54 | 0.932 |
| CRP level a, b, mg/L | 1.00 | 0.87 | 0.70 | 0.87 | 0.70 | 0.70 | 0.61-1.23 | 0.38-1.31 | 0.287 |
| ≥3.0 | 1.00 | 1.34 | 0.70 | 1.34 | 0.70 | 0.70 | 0.78-2.31 | 0.52-1.17 | 0.287 |
| <3.0 | 1.00 | 1.27 | 0.86 | 1.27 | 0.86 | 0.86 | 0.82-1.96 | 0.54-1.37 | 0.545 |
| Serum folate level a, b | 1.00 | 1.27 | 0.92 | 1.27 | 0.92 | 0.92 | 0.82-1.96 | 0.54-1.37 | 0.695 |
| High | 1.00 | 1.03 | 0.92 | 1.03 | 0.92 | 0.92 | 0.68-1.54 | 0.62-1.38 | 0.695 |
| Low | 0.527 |
| Liver damage level a, b | 1.66 | 0.63 | 0.63 | 1.49 | 0.53 | 0.53 | 0.50-5.49 | 0.14-2.86 | 0.536 |
| 1 | 1.00 | 1.46 | 1.11 | 1.46 | 1.11 | 1.11 | 0.87-1.89 | 0.66-1.89 | 0.716 |
| 2 | 1.00 | 0.83 | 0.84 | 0.83 | 0.84 | 0.84 | 0.56-1.24 | 0.57-1.24 | 0.398 |
| ≥3 | 1.00 | 1.39 | 1.49 | 1.39 | 1.49 | 1.49 | 0.46-4.19 | 0.53-4.20 | 0.461 |
| Presence of fatty liver a, b | 1.04 | 0.81 | 0.81 | 1.04 | 0.81 | 0.81 | 0.77-1.42 | 0.59-1.11 | 0.194 |
| Yes | 1.00 | 1.28 | 0.89 | 1.28 | 0.89 | 0.89 | 0.85-1.95 | 0.59-1.35 | 0.552 |
| No | 1.00 | 1.04 | 0.76 | 1.04 | 0.76 | 0.76 | 0.67-1.60 | 0.48-1.19 | 0.164 |
| Presence of cirrhosis a, b | 0.94 | 0.84 | 0.84 | 0.94 | 0.84 | 0.84 | 0.66-1.33 | 0.59-1.19 | 0.325 |
| Yes | 1.00 | 1.51 | 1.06 | 1.51 | 1.06 | 1.06 | 0.69-3.27 | 0.46-2.46 | 0.900 |
| No | 0.552 |
| BCLC stage a, b | 0.91 | 0.84 | 0.84 | 0.91 | 0.84 | 0.84 | 0.66-1.33 | 0.59-1.19 | 0.325 |
| 0/A | 1.00 | 1.51 | 1.06 | 1.51 | 1.06 | 1.06 | 0.69-3.27 | 0.46-2.46 | 0.900 |
| B/C | 0.653 |
| Treatment a, b | 1.00 | 0.94 | 0.84 | 1.00 | 0.94 | 0.94 | 0.66-1.33 | 0.59-1.19 | 0.325 |
| 0.292 |
| Covariate                  | HR   | 95% CI       | P-value |
|----------------------------|------|--------------|---------|
| Liver resection            | 1.00 | 1.24 (0.67-2.30) | 0.945   |
| Intervention               | 1.00 | 0.82 (0.57-1.17)  | 0.032   |
| Others                     | 1.00 | 1.41 (0.57-3.48)  | 0.668   |

**a** Covariates adjusted for age, sex, BMI, education level, smoking status, baseline liver damage level, BCLC stage, treatment, AFP level and CRP level.

**b** Stratified factors were not included in the corresponding models.